Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00938769 · ClinicalTrials.gov registry record · NA

Enhanced Self-Efficacy Training

A NA study of Neoplasms, sponsored by Duke University.

Completed
Registry status
NA
Development phase
358
Enrollment target
1
Study location

NCT00938769: Completed NA study of Neoplasms, sponsored by Duke University.

NCT00938769 is a NA study of Neoplasms that has completed, run by Duke University. The registered enrollment target is 358 participants, below the 1,619-participant average among 158 other Neoplasms trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00938769, a NA study of Neoplasms, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
358 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to examine the effects of an enhanced caregiver training protocol that not only teaches informal caregivers knowledge and skills for managing patient symptoms, but also provides strategies for managing their own psychological distress. The investigators anticipate this training will increase caregivers' self-efficacy and improve important caregiver outcomes (depression, anxiety, burden, quality of life) and patient outcomes (symptom distress/intensity, depression, anxiety, and quality of life). The study will compare the effects of this protocol to an education control condition that equates for interventionist time and attention.

Conditions Studied

Interventions

  • OTHER Self-Efficacy Training for Caregivers
  • OTHER Comparison Conditions for Caregivers

Study Locations (1)

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 358 participants
Start Date 2009-08
Est. Completion 2013-09
Phase NA
Duke University

1,725 total trials

What the finished NCT00938769 record still lists

NCT00938769 is an interventional study that assigns participants to a tested intervention. The registered 358 participants enrollment target is mid-sized for trials with a published cap, below the 1,619-participant average among 158 other Neoplasms trials with a reported enrollment target (78% lower).

The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Self-Efficacy Training for Caregivers is the first listed.

NCT00938769 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT00938769 about?

NCT00938769 is a clinical study titled "Enhanced Self-Efficacy Training". The goal of this study is to examine the effects of an enhanced caregiver training protocol that not only teaches informal caregivers knowledge and skills for managing patient symptoms, but also provides strategies for managing their own psychological distress. The investigators anticipate this trai...

What is the current status of trial NCT00938769?

This trial is currently completed. It is a NA study. The enrollment target is 358 participants. The study started on 2009-08. Estimated completion is 2013-09.

What conditions does trial NCT00938769 study?

This clinical trial studies the following conditions: Neoplasms.

What interventions are being tested in trial NCT00938769?

The interventions under investigation include: Self-Efficacy Training for Caregivers (OTHER), Comparison Conditions for Caregivers (OTHER).

Who is sponsoring clinical trial NCT00938769?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00938769 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00938769's enrollment target sits among peer trials

358 30th of 158 higher than 129 of 158 other Neoplasms trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04373317 · 358 participants · Phase 4

    Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

  • NCT05684965 · 358 participants · Phase 1

    XTX301 in Patients With Advanced Solid Tumors

  • NCT05824975 · 358 participants · Phase 1

    A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

  • NCT06480227 · 358 participants · NA

    Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00938769, the US trial registry maintained by the National Library of Medicine. NCT00938769 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.